339 related articles for article (PubMed ID: 22522623)
21. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
LeBlanc AK; Naik S; Galyon GD; Jenks N; Steele M; Peng KW; Federspiel MJ; Donnell R; Russell SJ
Hum Gene Ther Clin Dev; 2013 Dec; 24(4):174-81. PubMed ID: 24219832
[TBL] [Abstract][Full Text] [Related]
22. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
[TBL] [Abstract][Full Text] [Related]
23. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
[TBL] [Abstract][Full Text] [Related]
24. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.
Ben Yebdri F; Van Grevenynghe J; Tang VA; Goulet ML; Wu JH; Stojdl DF; Hiscott J; Lin R
Mol Ther; 2013 Nov; 21(11):2043-53. PubMed ID: 23985699
[TBL] [Abstract][Full Text] [Related]
25. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
26. PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.
Tesfay MZ; Kirk AC; Hadac EM; Griesmann GE; Federspiel MJ; Barber GN; Henry SM; Peng KW; Russell SJ
J Virol; 2013 Apr; 87(7):3752-9. PubMed ID: 23325695
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.
Stegelmeier AA; Chan L; Mehrani Y; Petrik JJ; Wootton SK; Bridle B; Karimi K
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882969
[TBL] [Abstract][Full Text] [Related]
28. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
[TBL] [Abstract][Full Text] [Related]
29. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
Gao Y; Bergman I
J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.
Kottke T; Tonne J; Evgin L; Driscoll CB; van Vloten J; Jennings VA; Huff AL; Zell B; Thompson JM; Wongthida P; Pulido J; Schuelke MR; Samson A; Selby P; Ilett E; McNiven M; Roberts LR; Borad MJ; Pandha H; Harrington K; Melcher A; Vile RG
Nat Commun; 2021 Mar; 12(1):1930. PubMed ID: 33772027
[TBL] [Abstract][Full Text] [Related]
31. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers.
Fehl DJ; Ahmed M
Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.
Ammayappan A; Peng KW; Russell SJ
J Virol; 2013 Dec; 87(24):13543-55. PubMed ID: 24089573
[TBL] [Abstract][Full Text] [Related]
33. Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy.
Muik A; Dold C; Geiß Y; Volk A; Werbizki M; Dietrich U; von Laer D
J Mol Med (Berl); 2012 Aug; 90(8):959-70. PubMed ID: 22286341
[TBL] [Abstract][Full Text] [Related]
34. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
[TBL] [Abstract][Full Text] [Related]
35. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.
Cook J; Peng KW; Witzig TE; Broski SM; Villasboas JC; Paludo J; Patnaik M; Rajkumar V; Dispenzieri A; Leung N; Buadi F; Bennani N; Ansell SM; Zhang L; Packiriswamy N; Balakrishnan B; Brunton B; Giers M; Ginos B; Dueck AC; Geyer S; Gertz MA; Warsame R; Go RS; Hayman SR; Dingli D; Kumar S; Bergsagel L; Munoz JL; Gonsalves W; Kourelis T; Muchtar E; Kapoor P; Kyle RA; Lin Y; Siddiqui M; Fonder A; Hobbs M; Hwa L; Naik S; Russell SJ; Lacy MQ
Blood Adv; 2022 Jun; 6(11):3268-3279. PubMed ID: 35175355
[TBL] [Abstract][Full Text] [Related]
36. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.
Willmon CL; Saloura V; Fridlender ZG; Wongthida P; Diaz RM; Thompson J; Kottke T; Federspiel M; Barber G; Albelda SM; Vile RG
Cancer Res; 2009 Oct; 69(19):7713-20. PubMed ID: 19773437
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.
Shulak L; Beljanski V; Chiang C; Dutta SM; Van Grevenynghe J; Belgnaoui SM; Nguyên TL; Di Lenardo T; Semmes OJ; Lin R; Hiscott J
J Virol; 2014 Mar; 88(5):2927-40. PubMed ID: 24371063
[TBL] [Abstract][Full Text] [Related]
38. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus.
Zhang P; Han X; Tan W; Chen D; Sun Q
Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430
[TBL] [Abstract][Full Text] [Related]
39. Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer.
Naik S; Galyon GD; Jenks NJ; Steele MB; Miller AC; Allstadt SD; Suksanpaisan L; Peng KW; Federspiel MJ; Russell SJ; LeBlanc AK
Mol Cancer Ther; 2018 Jan; 17(1):316-326. PubMed ID: 29158470
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
Saloura V; Wang LC; Fridlender ZG; Sun J; Cheng G; Kapoor V; Sterman DH; Harty RN; Okumura A; Barber GN; Vile RG; Federspiel MJ; Russell SJ; Litzky L; Albelda SM
Hum Gene Ther; 2010 Jan; 21(1):51-64. PubMed ID: 19715403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]